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Background: Patients with osteoarthritis commonly use complementary and alternative medicines (CAM),
either as an adjunct to or in place of conventional analgesics.
Objectives: To undertake a prospective investigation of the prevalence of CAM use for osteoarthritis and
the direct costs incurred.
Methods: The subjects were 341 patients with osteoarthritis of the knee or hip drawn from central and
northern Sydney, Australia, and comprising 83 community based patients and 258 awaiting joint
replacement. Information on CAM use was obtained from prospective three monthly diaries. Variables of
interest included health related quality of life scores. Prospective out of pocket costs were recorded over a
12 month follow up period.
Results: The prevalence of CAM use was 40%, which falls within the range of previous studies. Average
annual expenditure on CAM was A$32.25 (range 0 to 603.30). CAM users were more likely to be female
(odds ratio (OR) 1.8 (95% confidence interval, 1.1 to 3.0)), reported a higher level of bodily pain (OR
0.97 (0.95 to 0.99)), and were less likely to purchase conventional analgesics (OR 3.3 (1.6 to 7.0)), either
prescribed or over the counter. Vitamin supplementation was the most common CAM reported, followed
by celery extract, fish oils, and garlic extracts.
Conclusions: There are no good quality clinical trials to support the use of most preparations purchased by
patients with osteoarthritis. There is a need for patient education on the risks and benefits of
complementary medicine in osteoarthritis.
O
steoarthritis is a common chronic disabling disease,
with an estimated 21 million sufferers reported in the
USA,1 2 which corresponds to approximately 12.1% of
the population over the age of 25 years—similar to that in
Australia and other developed countries.3 4 Prevalence
increases with age,5 and so this number can only increase
as our population ages and treatments for life threatening
conditions improve. The cost to the health system is
substantial, measured in Australia at A$624 million in
1994,6 with 48% of these costs incurred in hospitals and 9%
for pharmaceuticals.
This comparatively small percentage for pharmaceuticals is
not surprising, as there is no preventive or curative drug
treatment available for osteoarthritis, and medical practi-
tioners are left simply with various analgesic options for the
pharmaceutical management of the disease. Despite a
recently described decrease in the use of paracetamol and
non-steroidal anti-inflammatory drugs (NSAID) in osteo-
arthritis,7 paracetamol, ibuprofen, and aspirin remain the
three most commonly used ‘‘over the counter’’ drugs for any
indication.8
In the absence of definitive treatments, do osteoarthritis
patients resort to using unproven alternative medicines as a
part of their disease management? For the purposes of this
study, ‘‘complementary and alternative medicines’’ (CAM)
have been defined as those medicinal preparations, either
oral or topical, which can be purchased over the counter
without medical prescription, do not have general medical
acceptance for their use, and do not include the analgesics
paracetamol, aspirin, or ibuprofen. Australia has a publicly
funded health care reimbursement system which does not
subsidise CAM, and there is no such reimbursement planned
in the future. Forty per cent of the population has additional
private health insurance, but this also does not provide for
most types of alternative medication.
Published reports to date are based on retrospective cross
sectional studies of CAM in osteoarthritis. To our knowledge,
there have been no prospective studies. In the present study
we undertook a prospective assessment of the patterns of
complementary and alternative medicine use and the
associated out of pocket costs in a population of osteoarthritis
sufferers in Sydney, and of independent predictive factors for
CAM use.
METHODS
Subjects
Two cohorts of osteoarthritis sufferers were recruited
between 1994 and 1999. Community dwelling subjects
with self reported osteoarthritis were drawn from
electoral rolls in the Northern Sydney health services
area. Questionnaires were sent to a random sample of
individuals from these rolls, and those who reported
having osteoarthritis were approached to participate.
The diagnosis of osteoarthritis was confirmed by
interview and physical examination by a rheumatologist
(described elsewhere9). We recruited 115 individuals with
osteoarthritis. In addition, nine orthopaedic surgeons
provided waiting lists for total primary hip or knee
replacements for four hospitals in Sydney (St Vincent’s
Public and Private Hospitals, the Centre for Bone and
Joint Disease, and Mater Misericordiae). Patients from
these lists with a diagnosis of osteoarthritis were
approached to participate in the study, and 399 were
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recruited. This study forms part of a larger ongoing NHMRC
funded study of the costs associated with arthritis, the COST
study.
Thirty two non-surgical patients and 141 surgical candi-
dates did not complete sufficient prospective diaries to allow
analysis (111 no longer wished to participate, 23 were
excused, 24 died, and 15 were unable to be contacted on
follow up).
Assessments
Baseline demographic information was collected, including
sex, age, employment status, highest level of education
achieved, comorbidities, duration of osteoarthritis, and
financial status determined by receipt of a pension.
Participants were asked to complete a retrospective three
month questionnaire detailing all expenses relating to their
arthritis, including prescription and non-prescription drug
costs. Quality of life at baseline was assessed by interview
using the Western Ontario and McMaster Universities
osteoarthritis index (WOMAC)10 and the medical outcomes
study short form 36 itme health survey (MOS SF-36)11. Lower
WOMAC scores reflect better performance; MOS SF-36 scores
are the reverse, with higher scores reflecting better perfor-
mance.
Patients were required to complete prospective cost diaries
every three months, recording medications purchased and
the amount spent on each preparation. Diaries were
completed by mail, and two reminder telephone calls made
if required. Diaries were checked for missing answers, and
clarifications made by telephone if required. It was specified
that only those preparations purchased for management of
osteoarthritis were to be recorded, both over the counter
treatments and prescription drugs. WOMAC and MOS SF-36
questionnaires were completed every three months for one
year by the surgical group; the non-surgical completed
WOMAC every three months, and MOS SF-36 at baseline
and 12 months.
Missing data
If a cost diary was not returned, the last record was carried
forward. There was no significant difference between the
four diaries (data not shown). This method was not
appropriate for postoperative diaries. In instances when
participants failed to return the amount spent on an item
within a diary, the missing cost of that individual item was
recorded as the mean expenditure for that item incurred by
that individual from the remaining diaries. Missing data
within the WOMAC and MOS SF-36 was dealt with using
guidelines specified by their authors. Where one entire
questionnaire was missing within the non-surgical group,
the result from the next returned questionnaire was
substituted.
Statistical methods
Data were analysed using the SPSS for Windows, version
11.0 program. Mean demographic differences between the
surgical and non-surgical groups were examined using x2
tests for dichotomous variables, and independent Student t
tests for continuous data. Paired sample t tests were used for
comparing results from different diaries. Univariate analyses
were carried out by Student’s t tests for continuous data, and
Mantel–Haenszel odds ratios were calculated for categorical
data. Backwards stepwise logistic regression was carried out
for multivariate analysis to identify independent predictors of
CAM use. In order to compare out of pocket expenditure over
time, all costs were adjusted to AU$1999 using the consumer
price index.
RESULTS
Demographics
The surgical group of osteoarthritis patients was older, more
likely to be on a pension or unemployed, but more highly
educated than the non-surgical group (table 1). There was no
significant difference between groups for duration of
osteoarthritis or the presence of other medical conditions.
Not surprisingly, the surgical group also performed more
poorly on most aspects of quality of life when compared with
the non-surgical group (table 2).
Once dropouts were excluded from the study, there were
83 non-surgical osteoarthritis participants and 258 surgical
patients enrolled. Dropouts were not significantly different
from those remaining in the study for any of the demo-
graphic factors. With respect to quality of life factors, non-
surgical dropouts were not different from the non-surgical
participants remaining in the study, with the exception of the
MOS SF-36 domain of bodily pain which was more severe in
the dropout group (mean score 41.0 in dropouts v 50.7 in
non-dropouts; t =22.39, p = 0.02). In the surgical group,
dropouts had significantly worse mean WOMAC pain scores
(11.1 v 10.2; t = 2.39, p = 0.02) and function scores (40.4 v
36.8; t = 2.73, p = 0.007), and poorer mean MOS SF-36
domain scores for physical function (dropouts 20.8 v 25.8 for
non-dropouts, t =22.45, p = 0.02), general health (64.2 v
70.1; t =22.40, p = 0.02), and social function (53.4 v 60.4;
t = 2.13, p = 0.03).
Table 1 Demographics of surgical and non-surgical
osteoarthritis participants
Variable
Non-surgical
(n = 115)
Surgical
(n = 399) p Value
Age (years) (mean (SD)) 65.0 (8.80) 68.5 (9.80) 0.001
% Female 67.0% 53.4% 0.032
Duration of disease (years)
(mean (SD)) 15.3 (12.1) 15.2 (11.8) NS
% On pension 45.2% 56.4% 0.034
% employed 29.6% 16.8% 0.002
% HSC or higher 46.8% 60.9% 0.008
% Comorbidities 67.8% 63.4% NS
% On non-prescription
medications 49.6% 46.4% NS
Table 2 Baseline quality of life scores in surgical and
non-surgical osteoarthritis participants
Mean score
Non-surgical
(n = 83) Surgical (n = 258)p Value
WOMAC pain 7.19 (3.7) 10.2 (3.9) ,0.0001
WOMAC stiffness 3.2 (1.6) 4.7 (1.7) ,0.0001
WOMAC function 23.5 (13.2) 36.8 (12.8) ,0.0001
MOS SF-36 domains
Physical function 50.1 (25.3) 26.0 (18.6) ,0.0001
Role physical 42.4 (42.6) 16.0 (29.5) ,0.0001
Bodily pain 50.8 (24.2) 33.3 (19.8) ,0.0001
General health 65.68 (21.2) 70.1 (19.6) 0.143
Vitality 55.0 (18.5) 47.2 (26.3) 0.035
Social function 76.6 (25.0) 60.5 (28.0) ,0.0001
Role emotional 70.2 (40.5) 58.8 (44.6) 0.079
Mental health 77.8 (15.1) 72.7 (19.6) 0.067
MOS SF-36 physical
summary 35.7 (11.5) 28.7 (6.4)
p,0.0001
MOS SF-36 mental
summary 53.6 (10.4) 48.8 (6.2)
p,0.0001
Values are mean (SD).
MOS SF-36, medical outcomes study SF-36 health survey; WOMAC,
Western Ontario and McMaster Universities osteoarthritis index.
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There were no significant differences between WOMAC
scores at baseline and at three, six, nine, or 12 months within
the non-surgical group, with the exception of mean stiffness,
which deteriorated between the first two diaries (3.2 at
baseline compared with 3.5 at three months; t =22.15,
p = 0.03). This was not considered to be a clinically important
difference. There were no significant differences between
mean MOS SF-36 scores over the 12 month period, with the
exception of the ‘‘role physical’’ score which improved (35.8
at baseline v 50.4 at 12 months; t =24.27, p,0.0001).
Comparisons of these variables between other diaries did not
reach statistical significance. There was significant improve-
ment in all the variables after surgery, reported elsewhere.12–14
Complementary and alternative medicines
Forty per cent of the combined surgical and non-surgical
cohort of osteoarthritis patients (136 of 341) purchased at
least one complementary medicine over the first 12 month
period of the study. These included 36 of the 83 non-surgical
participants (43%)—significantly different to the 53% report-
ing CAM use retrospectively in the three month period
leading up to the study (x2 = 19.41, p,0.0001). The non-
surgical group also reportedly spent more on CAM in the
retrospective period, with the average expenditure reported
as A$20.71 for the three months leading up to the start of the
study, compared with A$10.73 measured prospectively for the
first three months (t = 3.64, p,0.0001). Eighty one surgical
participants completed a prospective three month diary
preoperatively; of these, 17 (21%) recorded at least one
CAM purchase. This was a lower proportion than the 35
participants (43%) who retrospectively reported CAM pur-
chases in the three months before enrolling in the study
(x2 = 6.60, p = 0.01). In the first postoperative year, 94 of the
258 surgical participants (36%) purchased CAM.
There was no significant difference in overall CAM use
between the non-surgical group and those surgical partici-
pants who completed a three month diary before undergoing
joint replacement surgery (x2 = 2.27, p = 0.13), although
when different types of CAM are examined, the non-surgical
group was more likely to use oral herbal medicines than the
presurgical group (x2 = 8.51, p = 0.004).
The most common complementary medicines and prepara-
tions purchased by the study group over the first 12 months
of the study are shown in table 3.
There was no significant difference in expenditure between
any diaries in the non-surgical group (p.0.2) (data not
shown). Glucosamine sulphate and chondroitin sulphate
preparations were excluded from further analysis as they are
no longer considered to be CAM; their exclusion did not
change the results significantly, as they were infrequently
used in these cohorts. Annual mean costs were not different
between surgical and non-surgical participants (A$28.88 v
A$42.69; p = 0.2). The groups were therefore combined in all
further analyses. Mean (SD) annual expenditure on CAM for
the whole osteoarthritis cohort was A$32.25 (81.10), ranging
from no outlay to A$603.30. An average of A$80.85 (A$84.84
by men and A$78.75 by women) was spent by those
individuals who report spending on CAM. This makes up
approximately 33% of the total out of pocket non-surgical
costs of osteoarthritis in men, and 15% in women15 over the
same period of study.
Univariate associations with CAM use
The entire osteoarthritis cohort (n = 341) was classified as
‘‘purchased CAM in the study year’’ or ‘‘did not purchase
CAM in the study year.’’ Univariate associations with CAM
use (tables 4 and 5) included the three mean WOMAC
measures of disease impact over the study period, the mean
physical domains of the MOS SF-36, sex, and the use of
conventional analgesic drugs. Women were twice as likely to
use CAM as men, and individuals purchasing analgesics
(either over the counter or prescription) were 80% less likely
to purchase CAM products than those not using analgesics.
Those individuals purchasing CAM had more pain and
stiffness and poorer function on the WOMAC scale than
those who did not, both at baseline and on follow up. Similar
results were seen using the MOS SF-36 instrument, with
physical indices being worse in individuals using CAM. The
mental and emotional indices were generally not different,
except for the mental health scale which showed a
significantly worse score among the CAM purchasers, though
the difference was small. Educational level, socioeconomic
status, and age were not associated with CAM use.
Logistic regression model
The significant univariate independent variables for CAM use
were entered into a stepwise backwards logistic regression
analysis. The only factors found to be independent predictors
of CAM use were female sex, non-use of conventional
analgesics, and poorer score on the MOS SF-36 measure of
bodily pain (table 6). WOMAC function remained in the
model for stability, but did not reach statistical significance.
DISCUSSION
The prevalence of complementary medicine use in Australian
osteoarthritis sufferers (40%) is comparable to that seen in
the general community in Australia,16 despite the fact that
they are older and approximately 50% receive a pension.
Previous studies have reported a considerable range in this
estimation between populations, from 8% in older osteoar-
thritis patients in the USA17 to 54% of general rheumatology
patients in Canada18 and 70% among fibromyalgia sufferers.19
The reasons behind these differences are not clear, but are
likely to reflect cultural acceptance of alternative therapies,
availability and affordability of alternative choices, and the
adequacy of conventional medicine in caring for chronic,
painful, and often disabling diseases. The use of comple-
mentary medicines does not preclude traditional medical
care; Rao showed that 83% of CAM users also consult their
medical practitioner about their condition, although 72% of
these do not disclose their CAM use to that practitioner.20
Study participants uniformly overestimated the amount
they spend on CAM when giving information on a recall
basis. A higher proportion of participants reported purchas-
ing CAM in the preceding three months than in the ensuing
12 months, suggesting bias in the retrospective data
collection. The discrepancy between retrospective and pro-
spective diaries infers a certain unreliability of conclusions
about CAM use based on self report alone; for this reason,
Table 3 Number of participants who purchased the
more commonly reported complementary preparations
for osteoarthritis, and the average amount spent per
person
CAM
Non-surgical
(n = 83)
Surgical
(n = 258)
Total
(n = 341)
Vitamin supplements 10 38 48 (14%)
Fish oils 8 8 16 (5%)
Mussel extracts 4 5 9 (3%)
Celery extract 14 10 24 (7%)
Garlic 5 13 18 (5%)
Evening primrose oil 9 11 20 (6%)
Cod liver oil 4 13 17 (5%)
Goanna oil 5 11 16 (5%)
Average cost of CAM (per
person who purchased CAM) A$42.69 A$28.88 A$32.25
CAM, complementary and alternative medicines.
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further analysis was not done on the retrospective data
collected. This is an interesting finding in that most other
studies into the use of complementary medicines and
alternative health providers are based on patient recall and
estimation of usage and expenditure. The use of prospective
diary collection is a strength of this study, and has not
previously been carried out in studies of CAM in osteo-
arthritis. One could postulate that such bias is caused by
participants reporting all expenses they could remember
instead of limiting them to the specified three month period.
There may also have been a direct effect of the study on the
participants—being required to record all expenditures may
have forced patients to consider the cost of such preparations
before purchasing them. It is possible that participants forgot
to record purchases in the diaries, leading to the lower
reported rate compared with retrospective reporting; how-
ever, other reported variables such as prescription drugs and
visits to practitioners did not change in this patient
population15 so this is less likely.
Our study has shown that osteoarthritis sufferers in
Australia purchase a wide variety of herbal preparations as
treatment for joint disease; however, there is little good
quality evidence to support their use. There is no level 1
(meta-analysis of randomised controlled trials) or level 2
(well designed randomised controlled trial) evidence to
support the efficacy of any of the eight most popular
complementary medicines in our cohort (table 3).
Contributing to the lack of evidence is the poor quality of
even the randomised clinical trials of CAM21 and the
substantial publication bias surrounding the subject.22
The most popular patient initiated treatment for osteoar-
thritis was ‘‘vitamin supplementation.’’ Antioxidant vitamins
have been linked to improved osteoarthritis outcomes23—
particularly vitamin C, b carotene, and vitamin E—but there
is no association between osteoarthritis measures and non-
oxidative vitamin supplements. Ginger,24 25 topical capsai-
cin,26 and Devil’s claw27–29 have also been shown to give
symptomatic improvement in osteoarthritis.
Of all the available complementary medicines for osteoar-
thritis, glucosamine sulphate and chondroitin sulphate are
the two which are breaching the gap between ‘‘alternative’’
and ‘‘conventional’’ therapy. Originally considered a natural
therapy for osteoarthritis, the evidence of symptom improve-
ment with glucosamine30 31 is building to the point where
practitioners are accepting glucosamine preparations as a
routine step in the long term management of osteoarthritis.
Recent studies suggest not merely symptom modification but
also cartilage structural modification with glucosamine
sulphate.32–34
Chondroitin sulphate is effective in reducing pain in
osteoarthritis by at least half (measured by visual analogue
scale), as was shown in a meta-analysis of seven trials
Table 4 Univariate associations of continuous variables with the purchase of
complementary medicines in the entire osteoarthritis cohort
Continuous variables
Bought complementary
medicines
Did not buy
complementary
medicines t Value p Value
Age (years) 66.4 (9.2) 67.4 (9.1) 1.008 0.31
Disease duration (years) 14.4 (11.7) 16.0 (11.4) 1.261 0.21
WOMAC pain 5.7 (3.3) 4.6 (3.6) 22.986 0.003*
WOMAC stiffness 3.2 (1.5) 2.7 (1.6) 22.801 0.005*
WOMAC function 21.8 (12.2) 18.7 (13.3) 22.206 0.028*
SF-36 mental component summary 46.1 (5.3) 45.8 (5.0) 20.520 0.60
SF-36 physical component summary 36.8 (9.3) 39.6 (9.0) 2.427 0.016*
SF-36 scale scores
Mental health 0–100 73.3 (14.5) 76.8 (15.5) 2.099 0.037*
Role emotional 66.8 (34.2) 71.4 (33.7) 1.203 0.23
General health 65.6 (16.7) 67.5 (18.0) 0.987 0.33
Vitality 56.3 (14.6) 60.0 (18.7) 1.936 0.054
Social function 68.8 (34.2) 71.4 (33.7) 1.717 0.087
Physical function 47.7 (20.5) 53.5 (24.7) 2.251 0.025*
Role physical 39.3 (50.1) 50.3 (37.9) 2.294 0.022*
Bodily pain 52.5 (20.0) 63.3 (22.5) 4.496 0.001*
Cost of concomitant arthritis medicines
(annual, both prescription and non-
prescription) $98.27 ($113.35) $64.00 ($142.33)
22.458
0.014*
Values are mean (SD).
*p,0.05.
SF-36, short form 36 item health questionnaire; WOMAC, Western Ontario and McMaster Universities
osteoarthritis index.
Table 5 Univariate associations of categorical variables with the purchase of
complementary medicines in the entire osteoarthritis study group
Categorical variables b statistic SE p value Odds ratio 95% CI
Analgesic use 21.524 0.350 ,0.001 0.22 0.11 to 0.43
Sex (female) 0.746 0.228 0.001 2.11 1.35 to 3.30*
Education (higher) 0.213 0.223 0.38 1.24 0.80 to 1.92
Comorbidities 20.38 0.237 0.10 0.74 0.46 to 1.17
Pension 0.249 0.223 0.27 1.28 0.83 to 1.99
Employment 20.468 0.302 0.12 0.63 0.35 to 1.14
Planned surgery for
osteoarthritis (worse disease) 0.637 20.451 0.080 0.64 0.39 to 1.05
*p,0.05.
CI, confidence interval.
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measuring similar outcomes.35 There is a suggestion that
chondroitin may also play a role in disease modification,
retarding the progression of osteoarthritis in the knee36 37 or
hand38; to date, these results have only been published in
abstract form and it remains to be seen whether the quality of
the studies stands up to critical analysis.
This study of costs incurred by patients with osteoarthritis
was conducted between 1995 and 1999, in a period when the
benefits of glucosamine and chondroitin were only just
becoming known, and the preparations were not readily
available to patients in Australia. This is reflected in the
dearth of glucosamine and chondroitin use in our cohort; one
patient reported using ‘‘shark’s cartilage’’ in the retrospective
three month period, one prospectively reported purchasing
deer antler (containing various glycosaminoglycans including
glucosamine) in one three month period only, and one
postsurgical patient was maintained on glucosamine therapy
throughout the 12 month follow up period.
The vast majority of preparations purchased by our cohort
are not supported by evidence based medicine for use in
osteoarthritis. Similarly, most CAM preparations that are
supported by appropriate clinical trials39–42 are not represented
in our cohort. Despite a general lack of understanding of
complementary medicines in the osteoarthritis community,
we see that up to 33% of all patient out of pocket costs
(excluding surgical expenses) are attributable to alternative
medicines.
This study has shown the use of complementary and
alternative medicines for osteoarthritis is associated with
female sex, non-use of conventional analgesics for osteo-
arthritis, and poorer physical health. The relation of CAM
use43 to visits to complementary medicine practitioners43 44
and to female sex has been reported previously in studies of
rheumatoid arthritis, and also in surveys of the general
population.16 45 Surveys of the patients of rheumatologists
have been more divided with respect to other demographics,
with only a few revealing any relation between CAM use and
higher education,20 46 employment,16 and age.43 Some associa-
tion has been found previously between general health and
CAM use; one study of older patients with arthritis showed
that CAM users more commonly self reported a poorer health
state,47 and another showed that those patients consulting a
complementary health practitioner had ‘‘worse health’’ than
those who did not seek such intervention.48
Our non-surgical group was found to improve by a
clinically meaningful amount in their SF-36 measure of ‘‘role
physical’’ over the 12 month study. This is likely to be a
Bonferroni error; if the change is a real one, it might be
explained by the patient’s desire to do well, or be a result of
the ‘‘intervention’’ of the study itself. It would be unusual,
however, for this to affect only one quality of life measure.
The improvement is not related to CAM use.
Complementary and alternative medicine use in this study
was associated with both higher pain levels and the use of
less conventional analgesics. It is not possible to infer
causation here owing to the cross sectional study design,
but one might hypothesise that quality of life with regard to
pain could be improved by substituting simple analgesics in
this group, in addition to saving money.
Limitations of this study are those common to all cross
sectional studies.
It is only possible to describe associations between groups,
not look at the effect of CAM as an intervention in
osteoarthritis. It is therefore not possible to draw conclusions
regarding the efficacy of CAM. One can hypothesise that
CAM, as used by patients with less severe osteoarthritis in
northern Sydney, are not effective in symptom control, as this
prevalence paper has shown no evidence of improved health
status measures over a 12 month period in those taking CAM.
There was a high percentage of patients lost from the initial
cohort. These were shown to have more severe osteoarthritis
as reflected in health related quality of life measures than the
study group. This would suggest that the true prevalence of
CAM use in patients with osteoarthritis may have been
underestimated, given that CAM use has been shown to be
related to poorer pain and function outcomes.
Our study confirms that there is a significant proportion of
osteoarthritis sufferers in Australia who are using comple-
mentary or alternative medicines as an adjunct to their
conventional medical care, but the preparations they are
using have little or no scientific evidence of efficacy. Further
work is needed to define the efficacy and safety of CAM
preparations. The challenge is to demystify these treatments
and to improve the education of patients and medical
practitioners alike as to what can benefit osteoarthritis, what
is safe to use in arthritis, what can interact with other
conventional medicines, and what can be dangerous. Patients
with osteoarthritis are already using CAM; it is up to the
medical profession to be aware of what they are taking, and
to play an active role in patient education regarding the
available evidence base.
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